{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-019881","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.407958+00:00","generated_at":"2026-06-01T05:04:39.198071+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Monopar expands NorthStar collaboration; secures Ac-225 supply & full MNPR-101 IP ownership","bullets":["Long-term master supply agreement for actinium-225 from NorthStar for Monopar's development and commercial programs.","Monopar acquires full ownership of MNPR-101 radiopharmaceutical platform and related jointly developed IP from NorthStar.","Both companies share ownership of filed patent application on PCTA linker with Ac-225, showing superior binding vs. DOTA.","NorthStar expected to be first commercial-scale producer of non-carrier added Ac-225 using electron accelerator technology.","No financial terms disclosed; collaboration builds on NorthStar's Ac-225 manufacturing and Monopar's preclinical results."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-019881","json":"https://secwatch.observer/filing/0001437749-24-019881.json","markdown":"https://secwatch.observer/filing/0001437749-24-019881.md","text":"https://secwatch.observer/filing/0001437749-24-019881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924019881/0001437749-24-019881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924019881/mnpr20240610_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:04:39.198071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}